Exelixis Inc
XETRA:EX9
Exelixis Inc
XETRA:EX9
Price:
21.09
EUR
Market Cap:
€6.8B
Relative Value
The Relative Value of one
EX9
stock under the Base Case scenario is
20.35
EUR.
Compared to the current market price of 21.09 EUR,
Exelixis Inc
is
Overvalued by 3%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EX9
Relative Value
Base Case
20.35
EUR
Overvaluation 3%
Multiples Across Competitors
EX9 Competitors Multiples
Exelixis Inc Competitors
Exelixis Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Exelixis Inc
XETRA:EX9
|
10.8B EUR | 4.6 | 13.7 | 10.5 | 10.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
396.4B USD | 6.5 | 94.6 | 15.5 | 21.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.8B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.6B USD | 6.1 | 21.1 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.8B USD | 9.6 | 29.1 | 21.9 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.3B USD | 5.6 | 17.8 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3.2 | 34.8 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
38B EUR | 10.8 | 34.6 | 37.5 | 38.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
